Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor

被引：0
|
作者：
Lumb, Simon [1 ]
Fleischer, Sarah J. [2 ,3 ]
Daridon, Capucine [2 ,3 ]
Maloney, Alison [1 ]
Shock, Anthony [1 ]
Dorner, Thomas [2 ,3 ]
机构：
[1] UCB Pharma, Slough, Berks, England
[2] Charite, Dept Med Rheumatol & Clin Immunol, CC12, D-13353 Berlin, Germany
[3] German Rheumatism Res Ctr Berlin DRFZ, Berlin, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1108
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor
    Simon Lumb
    Sarah J. Fleischer
    Annika Wiedemann
    Capucine Daridon
    Alison Maloney
    Anthony Shock
    Thomas Dörner
    Journal of Cell Communication and Signaling, 2016, 10 : 143 - 151
  • [2] Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor
    Lumb, Simon
    Fleischer, Sarah J.
    Wiedemann, Annika
    Daridon, Capucine
    Maloney, Alison
    Shock, Anthony
    Doerner, Thomas
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2016, 10 (02) : 143 - 151
  • [3] Phosphoprotein Changes Induced with Epratuzumab, an Antibody Targeting CD22 On B Cells
    Lumb, S.
    Torbett, N.
    Vandrell, I.
    Turner, H.
    Page, M.
    Hales, P.
    Maloney, A.
    Vanhaesebroeck, B.
    Cutillas, P.
    Shock, A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S749 - S749
  • [4] Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
    Giltiay, Natalia V.
    Shu, Geraldine L.
    Shock, Anthony
    Clark, Edward A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S855 - S855
  • [5] Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
    Giltiay, Natalia V.
    Shu, Geraldine L.
    Shock, Anthony
    Clark, Edward A.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [6] EPRATUZUMAB, AN ANTIBODY TARGETING CD22 ON B CELLS, INDUCES PHOSPHOPROTEIN CHANGES FOLLOWING B-CELL RECEPTOR ACTIVATION IN VITRO
    Lumb, S.
    Torbett, N.
    Vendrell, I.
    Turner, H.
    Page, M.
    Hales, P.
    Maloney, A.
    Vanhaesebroeck, B.
    Cutillas, P.
    Shock, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 179 - 179
  • [7] IN VIVO EFFECTS OF EPRATUZUMAB, A MONOCLONAL ANTIBODY TARGETING HUMAN CD22, ON B CELL FUNCTION IN HUMAN CD22 KNOCK-IN (HUKI) MICE
    Brandl, C.
    Oezgoer, L.
    Woehner, M.
    Shock, A.
    Nitschke, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 811 - 811
  • [8] In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
    Brandl, Carolin
    Oezgoer, Lamia
    Woehner, Miriam
    Shock, Anthony
    Nitschke, Lars
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S855 - S856
  • [9] Targeting of CD22 by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation
    Sieger, N.
    Fleischer, S. J.
    Reiter, K.
    Mei, H. E.
    Shock, A.
    Burmester, G.
    Daridon, C.
    Dorner, T.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S749 - S749
  • [10] Epratuzumab, a monoclonal antibody targeting CD22, inhibits BCR/CD40-stimulated B cell proliferation in vitro
    Fossati, G.
    Rapecki, S.
    Maloney, A.
    Shock, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S5 - S5
12345